Lindbrook Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Lindbrook Capital’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-144	Closed	-$3K	–	2258
2021 Q3	$3K	Buy	+144	New	+$1.68K	﹤0.01%	1478
2020 Q4	–	Sell	-1,500	Closed	-$21K	–	1919
2020 Q3	$21K	Hold	1,500	–	–	0.01%	597
2020 Q2	$12K	Sell	1,500 -8,500	-85%	-$52.6K	﹤0.01%	791
2020 Q1	$40K	Buy	+10,000	New	+$37.8K	0.02%	375

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Lindbrook Capital's TRIL Position: Q4 2021 in Review

Lindbrook Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 144 shares — an estimated $3K sold.

Lindbrook Capital first reported a position in TRIL in Q1 2020 and held it in 4 quarters. The position peaked at $40K in Q1 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Lindbrook Capital reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Lindbrook Capital sold 144 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $3K.
Lindbrook Capital first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 4 quarters.
Lindbrook Capital's Trillium Therapeutics Inc. position peaked at $40K in Q1 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.